Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 704 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CC5013 Clear all

Conditions: Newly Diagnosed Multiple Myeloma (NDMM)
Interventions: AZD0120, Cyclophosphamide, Fludarabine, Melphalan (part of ASCT), Lenalidomide; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2039
U.S. locations: 46
States / cities: Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 37 more

Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions: Revlimid; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Bortezomib, Lenalidomide, Dexamethasone, Stem Cell Mobilization, Autologous Stem Cell Transplant; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 8
States / cities: Denver, Colorado • Brewer, Maine • Boston, Massachusetts + 3 more

Conditions: Leukemia, CLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Lenalidomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Plasma Cell Myeloma, Renal Failure
Interventions: Bortezomib, Daratumumab, Dexamethasone, Lenalidomide, Thalidomide; Drug · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: High Dose Methylprednisolone (HDMP), Ofatumumab, Lenalidomide; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Multiple Myeloma
Interventions: Bortezomib, Lenalidomide, Dexamethasone, Vorinostat; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Multiple Myeloma
Interventions: VELCADE (bortezomib), dexamethasone, cyclophosphamide, Revlimid (lenalidomide); Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Denver, Colorado • Rochester, Minnesota

Conditions: Relapsed or Refractory Multiple Myeloma (RRMM)
Interventions: BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Dexamethasone, Elranatamab; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Multiple Myeloma
Interventions: Bort, Dex, and Dox with ALCAR; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 5
States / cities: Janesville, Wisconsin • La Crosse, Wisconsin • Madison, Wisconsin + 2 more

Conditions: Plasma Cell Leukemia in Remission, Plasma Cell Myeloma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim, Laboratory Biomarker Analysis, Lenalidomide, pheresis, Melphalan, Palifermin, Total Marrow Irradiation; Procedure · Drug · Biological + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Duarte, California

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: ABBV-453, Dexamethasone, Daratumumab, Lenalidomide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Stanford, California • Miami, Florida • New Orleans, Louisiana + 9 more

Conditions: Healthy
Interventions: Lenalidomide, Quinidine, Temsirolimus, Diphenhydramine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Epcoritamab, Lenalidomide; Biological · Drug
Lead sponsor: Genmab; Industry
Eligibility: 75 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Waukesha, Wisconsin

Conditions: Refractory Multiple Myeloma
Interventions: bendamustine hydrochloride, lenalidomide, dexamethasone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 5
States / cities: Duarte, California • Jacksonville, Florida • Chicago, Illinois + 2 more

Conditions: Cutaneous Lupus Erythematosus (CLE)
Interventions: Lenalidomide; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multiple Myeloma, Amyloidosis
Interventions: APG-2575+ Pd, APG-2575 + DRd; Drug
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Jacksonville, Florida • New York, New York • Cleveland, Ohio

Conditions: Multiple Myeloma
Interventions: bb2121, Fludarabine, Cyclophosphamide, Lenalidomide; Biological · Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more

Conditions: Multiple Myeloma
Interventions: Belantamab mafodotin, Nirogacestat, Lenalidomide, Dexamethasone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions: Lenalidomide, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 13
States / cities: San Diego, California • Denver, Colorado • Chicago, Illinois + 9 more

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Tafasitamab, Tafasitamab plus lenalidomide; Drug
Lead sponsor: MorphoSys AG; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 23
States / cities: Tucson, Arizona • Anaheim, California • Duarte, California + 20 more

Conditions: Multiple Myeloma
Interventions: Medication Event Monitoring System; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 65 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Multiple Myeloma, Renal Failure
Interventions: Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone; Combination Product
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Augusta, Georgia

Search by objective public record fields.

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)

Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Lenalidomide Adherence in Older Adults

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure